Gilead and arcus biosciences announce positive update on joint tigit program from interim analysis of arc-7 study in non-small cell lung cancer

Foster city, calif. & hayward, calif.--( business wire )--gilead sciences, inc. (nasdaq: gild) and arcus biosciences (nyse: rcus) today announced a positive update from the fourth interim analysis of the randomized, open-label phase 2 arc-7 study in patients with first-line metastatic non-small cell lung cancer (nsclc) with pd-l1 tumor proportion score (tps) ≥50% without epidermal growth factor receptor or anaplastic lymphoma kinase (egfr/alk) mutations. arc-7 is evaluating the combinations of anti-tigit antibody domvanalimab plus anti-pd-1 antibody zimberelimab (doublet), and domvanalimab plus zimberelimab and etrumadenant, an a2a/b adenosine receptor antagonist (triplet), versus zimberelimab alone, and represents the first randomized phase 2 study of an fc-silent anti-tigit/anti-pd-1 combination. the protocol-specified fourth interim analysis was conducted when the trial reached full enrollment, with a clinical data cutoff date of august 31, 2022. a total of 150 patients have been randomized across the three study arms.
RCUS Ratings Summary
RCUS Quant Ranking